1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Drug Analysis: darolutamide

Drug Analysis: darolutamide

  • January 2018
  • 17 pages
  • ID: 5336436

Summary

Table of Contents

Drug Overview
Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to ARs, blocking nuclear translocation of ARs and AR-mediated gene expression.

The AR signaling pathway is the primary pathway that drives prostate cancer growth.
Darolutamide will have to demonstrate improved efficacy and tolerability or be priced competitively to gain market share in an increasingly crowded prostate cancer market. Darolutamide is an AR antagonist similar to established AR inhibitor Xtandi (enzalutamide; Pfizer/Astellas).

Bayer is currently investigating darolutamide in high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in two Phase III trials. Late-phase data are needed to determine the commercial potential of darolutamide, but, if approved, the drug will face strong competition from Xtandi as well as from blockbuster hormonal therapy Zytiga (abiraterone acetate; Johnson and Johnson/AstraZeneca).

Xtandi has proven efficacious in nmCRPC in the Phase III PROSPER study, and Zytiga was recently approved for use in mHSPC patients following success in the Phase III LATITUDE trial. Further, darolutamide will face direct competition from late-phase AR inhibitor apalutamide (Johnson and Johnson) in both the nmCRPC and mHSPC populations.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Ablation Equipments - Medical Devices Pipeline Assessment, 2018

Ablation Equipments - Medical Devices Pipeline Assessment, 2018

  • $ 4000
  • Industry report
  • August 2018
  • by GlobalData

Ablation Equipments - Medical Devices Pipeline Assessment, 2018SummaryGlobalData’s Medical Devices sector report, “Ablation Equipments - Medical Devices Pipeline Assessment, 2018" provides an overview ...

Metastatic Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

Metastatic Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

  • $ 700
  • Industry report
  • June 2018
  • by VPAResearch

Metastatic Prostate Cancer ongoing clinical trials report provides comprehensive analysis and trends in global Metastatic Prostate Cancer disease clinical trials. The research work analyzes the ongoing ...

Hormone-Sensitive Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

Hormone-Sensitive Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

  • $ 700
  • Industry report
  • June 2018
  • by VPAResearch

Hormone-Sensitive Prostate Cancer ongoing clinical trials report provides comprehensive analysis and trends in global Hormone-Sensitive Prostate Cancer disease clinical trials. The research work analyzes ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on